Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted Antibody-Drug combo aims to tackle High-Risk bladder cancer

NCT ID NCT06187506

Ongoing Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests whether combining a targeted drug called disitamab vedotin with BCG therapy can improve outcomes for people with HER2-positive high-risk non-muscle invasive bladder cancer. The drug is given intravenously every three weeks, while BCG is delivered directly into the bladder. The trial will measure how many participants achieve complete remission at 3 months and how long they remain cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a targeted antibody-drug conjugate called disitamab vedotin combined with BCG (bacillus Calmette-Guerin) vaccine therapy
What this could lead to
If successful, this combination could offer a more effective treatment option for people with HER2-positive high-risk bladder cancer, potentially reducing the chance of recurrence or progression.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. The combination may cause side effects or not improve outcomes compared to standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER-2 PROTEIN OVEREXPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER-2 PROTEIN OVEREXPRESSION NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.